Abstract / Summary
Introduction: Garbhini Chhardi or Hyperemesis Gravidarum (HG) is a disabling and prevalent pregnancy condition involving severe vomiting and nausea. Management of the condition is necessary to preserve the health of the mother and foetus. Ayurveda has provided effective and safe measures for nausea and vomiting of pregnancy. Two Ayurvedic drugs, Bilvadi Vati and Kustumbaru Kalka Vati, are given in this condition. This research examines their effectiveness in the management of Garbhini Chhardi. Aim: To evaluate the clinical efficacy of Bilvadi Vati therapy for the management of Garbhini Chhardi (HG) with respect to the severity of nausea, vomiting frequency, hydration status, and overall improvement of maternal health compared to Kustumbaru Kalka Vati. Materials and Methods: The Randomised Controlled clinical Trial (RCT) was conducted in Ayurveda Mahavidyalaya of Sangam Sevabhavi Trust, Wardha, Maharashtra, India for 18 months from September 2019 to April 2021. A total of 90 pregnant women with Garbhini Chhardi were subjected to a RCT. The volunteers were divided into two groups randomly: Group A received Bilvadi Vati, and Group B received Kustumbaru Kalka Vati. The trial was conducted at Sangam Sevabhavi Trust’s Ayurveda Mahavidyalaya for four weeks. The inclusion criteria for the trial were pregnant volunteers aged 12 to 14 weeks pregnant, diagnosed with Garbhini Chhardi, and willing to participate. Clinical outcomes were measured with the Pregnancy-Unique Quantification of Emesis (PUQE) scale to measure the severity of nausea and vomiting. Frequency of vomiting and hydration level were also quantified. A statistical analysis using Statistical Package for the Social Sciences (SPSS) version 28.0. For pair-wise comparisons within groups, the Wilcoxon signed-rank test was used. Inter-group comparisons were performed with the help of the Mann-Whitney U test for comparisons between groups. Descriptive statistical parameters (mean, median, standard deviation) were employed for data summarising purposes, with a p-value <0.05. Results: Both groups significantly improved symptoms (p-value <0.001). Group A (Bilvadi Vati) improved more in Chardi and Daurbalya on intergroup comparison. Group A exhibited significant improvement (>60%) with 64.44% in Group A and 4.44% in Group B. Conclusion: The present study again establishes that Bilvadi Vati and Kustumbaru Kalka Vati effectively manage Garbhini Chhardi. However, Bilvadi Vati was more clinically effective with better relief of symptoms and a greater percentage of marked improvement, greater than 75% relief.